drugset / Trial / NCT02960061

Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer

NCT02960061

RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators intend to conduct a randomized controlled study to find if combining HIPEC (hyperthermic intraperitoneal perfusion chemotherapy) with post-neoadjuvant chemotherapy D2 resection could improve survival for patients with advanced gastric cancer, while comparing with the traditional approach of D2 resection after neoadjuvant chemotherapy.

Timeline

Start
2016-11
Primary completion
2019-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 100 mg/m2 Other
Background Docetaxel Small molecule 50 mg/m2
Background Leucovorin Small molecule 200 mg/m2
Background Oxaliplatin Small molecule 85 mg/m2
Background S-1 Small molecule
Background fluorouracil Small molecule 600 mg/m2 Intravenous

Indications

No indication recorded.